From the Journals

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

Share

In a nationwide cohort study in Taiwan, sodium-glucose cotransporter-2 inhibitors were linked to reduced risks of kidney, cardiovascular, and hepatic complications in patients with type 2 diabetes and cirrhosis over a median follow-up of 2.3 years. The study analyzed data from 24,259 patients, revealing that those treated with these inhibitors had a significantly lower incidence of end-stage kidney disease, acute kidney injury, major cardiovascular events, and hepatic decompensation compared to those on dipeptidyl peptidase-4 inhibitors. However, limitations including the lack of laboratory data on cirrhosis severity were noted.

Original Source(s)

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

  • by Henry Thomas

  • March 10, 2026

  • 2 min

Related Content

What Does Corporate Compliance Really Mean?

Corporate compliance isn’t just about avoiding fines; it’s an opportunity to shape culture, partnerships, and everyday decision-making

Mapping the Metabolism of Plant Mixtures 

A multilayer networking workflow reveals mixture-dependent metabolism of kratom alkaloids A multilayer networking workflow reveals mixture-dependent metabolism of kratom alkaloids 

  • March 10, 2026

  • 3 min
Diabetes Risk Assessment: A New Approach

Blood-based epigenetic markers show strong prognostic potential for Type 2 diabetes